Cerus Corporation $CERS Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. decreased its holdings in Cerus Corporation (NASDAQ:CERS) by 4.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,516,606 shares of the biotechnology company’s stock after selling 193,353 shares during the quarter. Amova Asset Management Americas Inc.’s holdings in Cerus were worth $8,220,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in CERS. Vanguard Group Inc. raised its position in shares of Cerus by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock worth $17,147,000 after purchasing an additional 62,663 shares during the last quarter. Wasatch Advisors LP boosted its stake in shares of Cerus by 2.6% in the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock worth $12,033,000 after acquiring an additional 213,917 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Cerus by 17.6% during the third quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock worth $5,517,000 after buying an additional 519,301 shares in the last quarter. Ieq Capital LLC lifted its stake in Cerus by 1.1% in the 4th quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock worth $4,993,000 after purchasing an additional 25,771 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Cerus by 5.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,676,279 shares of the biotechnology company’s stock worth $3,453,000 after purchasing an additional 92,577 shares during the last quarter. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cerus

In other news, CEO William Mariner Greenman sold 101,919 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total value of $299,641.86. Following the completion of the sale, the chief executive officer directly owned 5,053,036 shares of the company’s stock, valued at approximately $14,855,925.84. This represents a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Chrystal Jensen sold 24,329 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $2.94, for a total transaction of $71,527.26. Following the transaction, the insider owned 966,657 shares in the company, valued at approximately $2,841,971.58. This trade represents a 2.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 256,071 shares of company stock valued at $747,894 in the last quarter. Company insiders own 5.30% of the company’s stock.

Analyst Ratings Changes

CERS has been the topic of several recent analyst reports. BTIG Research upgraded shares of Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Friday, May 1st. Zacks Research upgraded shares of Cerus from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Cerus has an average rating of “Hold” and a consensus price target of $4.00.

Cerus Stock Up 0.6%

Shares of NASDAQ CERS opened at $3.15 on Tuesday. The stock has a market cap of $631.17 million, a P/E ratio of -63.00 and a beta of 1.77. The business’s fifty day simple moving average is $2.81 and its 200-day simple moving average is $2.38. Cerus Corporation has a 12-month low of $1.15 and a 12-month high of $3.47. The company has a current ratio of 1.63, a quick ratio of 1.06 and a debt-to-equity ratio of 0.47.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%.The company had revenue of $59.89 million for the quarter, compared to analyst estimates of $55.68 million. As a group, equities analysts predict that Cerus Corporation will post -0.02 EPS for the current fiscal year.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.